2013年6月23日訊 /生物谷BIOON/ --比利時(shí)制藥公司Cardio公司開始一次小規(guī)模的IPO,，計(jì)劃募集2800萬歐元（約合3700萬美元）以支持其一項(xiàng)在歐洲的關(guān)于心力衰竭藥物的晚期研究和在美國(guó)的一項(xiàng)研究的起始工作。在這次IPO中,，Cardio3公司原有投資者SRIW購(gòu)買了相當(dāng)多的股份,，也使市場(chǎng)懷疑公司能夠不依靠原有投資者,，獨(dú)立走向市場(chǎng)。（生物谷Bioon.com）
詳細(xì)英文報(bào)道：
The Belgian biotech Cardio3 BioSciences has mounted a relatively small €28 million ($36.95 million) IPO with a lot of help from previous investors. It aims to sell 1.3 million shares from €16.65 ($21.97) to €19 ($25.07) each between June 21 and July 3, raising money to fund the company's late-stage trial of a heart failure drug in Europe as well as work to begin a study of the therapy in the U.S., Reuters reported. As the news wire noted, SRIW and PMV have committed to buy €13.95 million ($18.41 million) of shares in the biotech group's IPO. SRIW is an existing investor, raising the question of whether the company could go public without the help of insiders.
